Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/11/2018 |
| Start Date: | March 2009 |
| End Date: | January 2011 |
A Randomized Trial to Evaluate the Benefit of High Dose Vitamin D3 on Aromatase Inhibitor Letrozole-Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).
The primary purpose is to determine if high dose vitamin D3 reduces the incidence of
musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with
early stage breast cancer and low serum vitamin D levels.
musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with
early stage breast cancer and low serum vitamin D levels.
The primary hypothesis is that high dose vitamin D3 plus standard dose vitamin D3 prevents
the worsening of musculoskeletal symptoms when compared to a standard dose vitamin D3
treatment. This protocol will examine the relationship between vitamin D levels
(25-hydroxyvitamin D) and various quality of life measures in women being treated with
letrozole as standard care for early stage breast cancer. All subjects received letrozole and
a standard dose of vitamin D3 (600 IU daily). Randomization was between high dose vitamin D3
(30,000 IU once per week) vs. a blinded, matched placebo,
the worsening of musculoskeletal symptoms when compared to a standard dose vitamin D3
treatment. This protocol will examine the relationship between vitamin D levels
(25-hydroxyvitamin D) and various quality of life measures in women being treated with
letrozole as standard care for early stage breast cancer. All subjects received letrozole and
a standard dose of vitamin D3 (600 IU daily). Randomization was between high dose vitamin D3
(30,000 IU once per week) vs. a blinded, matched placebo,
Inclusion Criteria:
- Post-menopausal women newly diagnosed with early stage breast cancer, who would be
treated with an aromatase inhibitor
- Serum 25OHD levels < 40 ng/ml
Exclusion Criteria:
- Severe or debilitating musculoskeletal pain
- Known metastatic disease
- History of renal stones
- History of hypercalcemia or hyperthyroidism
- Currently receiving adjuvant or neoadjuvant chemotherapy
- Currently receiving other investigational agents
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials